PROG Holdings, Inc. Q2 2025 Earnings Supplement July 23, 2025 PROG Internal Use of Forward-Looking Statements Statements, estimates and projections in this earnings supplement regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause actual results to differ materially from those contained in the forward-looking statements. Such forward-looking statements generally can be identified by the use of forward-looking terminology, ...

Q1 2026 Earnings Presentation July 23, 2025 1 Today's Presenters Zak Calisto Group CEO & Founder Goy Hoeshin Group CFO Carmen Calisto Group Chief Strategy & Marketing Officer 2 2 DISCLAIMER Forward-Looking Statements The information in this presentation (which includes any oral statements made in connection therewith, as applicable) includes "forward-looking statements." Forward-looking statements are based on our beliefs and assumptions and on information currently available to us, and include, without lim ...

Second Quarter 2025 Financial Results July 23, 2025 This presentation includes unaudited non-GAAP financial measures. Additional information about these measures, reconciliations to the nearest GAAP financial measures and additional information about the basis of the presentation of our second quarter financial results are provided in the appendix to this presentation. © 2025 Fiserv, Inc. or its affiliates Second Quarter Highlights See Appendix for information regarding non-GAAP financial measures. All comp ...

Financial Performance - ACV (Annual Contract Value) grew by 16%, or 14% in constant currency, reaching $1.514 billion as of June 30, 2025[60, 62] - Pega Cloud ACV experienced significant growth of 28%, or 25% in constant currency[21, 71, 75] - Free cash flow year-to-date (YTD) reached $286 million[21] - Total backlog increased by 31% to $1.835 billion[84] - Net ACV add for the first half of 2025 was $99 million, a 60% increase compared to the first half of 2024[78, 79] Market and Business Strategy - Pega is targeting a large market opportunity, estimated at over $90 billion in FY25 and projected to exceed $150 billion by FY29[26, 56] - The company is focused on a recurring subscription model and aims to drive ACV growth and leverage Pega Cloud[54, 66] - Pega emphasizes its technology leadership in customer engagement and intelligent automation[26] Technology and Solutions - Pega's platform offers enterprise AI decisioning and workflow automation[11] - Key solutions include 1:1 Customer Engagement, Customer Service, and Workflow Automation[12, 30] - Pega's architecture is designed for scalability and rapid innovation, featuring the Situational Layer Cake and Pega Express[13, 14]

Fact Sheet Fact Sheet Consolidated Financial Data - Second Quarter, Fiscal 2023 Consolidated Financial Data - First Quarter, Fiscal 2026 | 2.6% QoQ | 20.8% | 8.6% YoY | $3.8 Bn | $884 Mn | | --- | --- | --- | --- | --- | | 3.8% YoY CC Growth | Operating Margin | EPS Increase (₹ terms) | Large Deal TCV (55% Net New) | Free Cash Flow | Revenue Growth- Q1 26 | | Reported | C C | | --- | --- | --- | | QoQ growth (%) | 4.5% | 2.6% | | YoY growth (%) | 4.8% | 3.8% | Revenues by Business Segments | | | | | | (in % ...

Financial Performance - The company's reported net sales reached $5061 billion, demonstrating a 228% increase year-over-year[21] - Operational net sales grew by 216% year-over-year[14] - Organic net sales increased by 174% compared to the previous year[14] - Reported earnings per share (EPS) stood at $053, compared to $022 in Q2 2024[18] - Adjusted EPS was $075, up from $062 in Q2 2024[18] - The company's free cash flow reached $1129 million in Q2 2025, compared to $660 million in Q2 2024[35] Segment Performance - MedSurg segment reported net sales of $1716 billion, a 157% increase year-over-year[22] - Cardiovascular segment reported net sales of $3345 billion, a 268% increase year-over-year[25] - Cardiology segment net sales increased by 293% to $2647 billion[27] - Electrophysiology (EP) net sales surged by 961% to $840 million[27] Guidance - The company projects Q3 2025 reported net sales growth of 17%-19% and organic net sales growth of 12%-14%[18] - Q3 2025 reported EPS is expected to be $044-$046, with adjusted EPS of $070-$072[18] - For the full year 2025, the company anticipates reported net sales growth of 18%-19% and organic net sales growth of 14%-15%[18] - Full year 2025 reported EPS is projected to be $189-$193, with adjusted EPS of $295-$299[18]

Q2 2025 Results July 23, 2025 1 Cautionary note The following materials are for presentation purposes only. They accompany the discussions held during Rogers Communications Inc.'s (Rogers) investor conference call on July 23, 2025. Certain statements made in this presentation, including, but not limited to, statements relating to expected future events, financial and operating results, guidance, objectives, plans, strategic priorities and other statements that are not historical facts, are forward-looking. ...

Financial Performance & Outlook - Q2 2025 revenue increased by 30% year-over-year, but constant currency revenue decreased by 02%[88] - Gross margin improved to 325%, a 330 basis point increase compared to the previous year[88] - Adjusted EBITDA improved by $74 million year-over-year to $(36) million[88] - The company reaffirmed its 2025 Adjusted EBITDA outlook of $5 million to $15 million[20] - Capital expenditures for 2025 are expected to be approximately $20 million[20] Regional Performance - Europe & International segment revenue increased by 57% in constant currency[45] - Europe & International segment Adjusted EBITDA was 21% of revenue[45] - North America segment revenue was $63 million in Q2 2025[76] - Greater China foodservice revenue increased by 12% in H1[86] Strategic Initiatives - The company is undertaking a strategic review of its Greater China business[19] - The company is focused on aggressively pursuing cost efficiencies, aiming for a 10% year-over-year reduction in COGS per liter in H1[25] - The company is rolling out a refreshed playbook to ignite positive category momentum in more markets[18]

Transaction Overview - NATCO Pharma proposes to acquire a 35.75% shareholding in Adcock Ingram, a South African pharmaceutical company[3] - The price per share is ZAR 75, equating to US$4.271[3] - The total cost to NATCO is estimated at ZAR 4 Billion, approximately US$226 Million[3] - Transaction costs are projected to be around ₹ 2,000 Cr, roughly US$10 Million[3] Adcock Ingram Financials - Adcock Ingram's revenue was US$484 million in FY22, US$507 million in FY23, and US$536 million in FY24[3,22] - H1 FY25 revenue reached US$262 million[3,22] - EBITDA margins have been consistent, at 15% in FY22, 16% in FY23, and 15% in FY24, with 14% in H1 FY25[22] - Net profit margins were 9% in FY22, 10% in FY23, and 8% in FY24, with 8% in H1 FY25[22] Strategic Rationale - South Africa is a key emerging market and a gateway to the African continent, offering a strong regulatory environment[26] - Adcock Ingram is the second-largest pharmaceutical company in South Africa, with a presence across prescription, OTC, consumer, and hospital segments[5,26] Potential Synergies - NATCO aims to leverage Adcock Ingram's distribution network for its products in South Africa[29] - The partnership seeks to introduce affordable and innovative pharmaceutical products across African markets[29]

Mr. CooperGroup® 2Q'25 EARNINGS REVIEW July 23, 2025 IMPORTANT INFORMATION This presentation contains summarized information concerning Mr. Cooper Group Inc. ("Mr. Cooper" or the "Company") and the Company's business, operations, financial performance and trends. No representation is made that the information in this presentation is complete. For additional financial, statistical and business related information, as well as information reqarding business and segment trends, see the Company's most recent Ann ...